Andrew P. Beelen

1.1k citations

35 papers · 553 indexed · h-index 12

Genetics top 10%
- Estrogen and related hormone effects 3
Oncology top 10%
- HER2/EGFR in Cancer Research 9
- Cancer Treatment and Pharmacology 7
- Lung Cancer Research Studies 4
- Colorectal Cancer Treatments and Studies 3
Pharmacology top 10%
Hematology
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 14
Molecular Biology
- Cancer therapeutics and mechanisms 3
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 2

Co-authors: Lionel D. Lewis Kevin M. Koch Andrew G. Stead L. D. Lewis Nandi J. Reddy Roger B. Cohen Nancy Lewis Nikita Arya
Cited by: Genetics Oncology Pharmacology
Journals: Journal of Clinical Oncology (9 papers)Cancer Research (3 papers)Clinical Cancer Research (1 paper)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Andrew P. Beelen

34 papers receiving 534 citations

Peers

Countries citing papers authored by Andrew P. Beelen

Since Specialization

Citations

This map shows the geographic impact of Andrew P. Beelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Beelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Beelen more than expected).

Fields of papers citing papers by Andrew P. Beelen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Beelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Beelen. The network helps show where Andrew P. Beelen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew P. Beelen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew P. Beelen Line = papers co-authored together Andrew P. Beelen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial JNCI Cancer Spectrum ·Heinz‐Josef Lenz,Tianshu Liu,Emerson Y. Chen,Zsolt Horváth,Igor Bondarenko,Iwona Danielewicz,Michele Ghidini,Pilar García‐Alfonso,Robert H. Jones,Matti Aapro,Yanqiao Zhang,Jufeng Wang,Wayne Wang,Jennifer Adeleye,Andrew P. Beelen,Joleen M. Hubbard	2024	2
2	Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study. Journal of Clinical Oncology ·Jeremy Force,Joyce O’Shaughnessy,Lisa S. Wang,Kailash Mosalpuria,Sara A. Hurvitz,Shom Goel,Sarah Ahn,Subing Cao,Melissa L. Russo,John S. Yi,Taofik Oyekunle,Amanda Jacobson,Andrew P. Beelen,Michael Danso	2023	1
3	Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer Clinical Drug Investigation ·Chao Li,Janet K. Horton,Mark Sale,Laura Curd,Vineet Goti,Wenli Tao,Andrew P. Beelen	2022	4
4	Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer British Journal of Clinical Pharmacology ·Chao Li,Benjamin E. Rich,Julie Bullock,Olivier Barrière,Jean‐Francois Marier,Andrew P. Beelen	2022	3
5	Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3). Journal of Clinical Oncology ·Guru Sonpavde,Petros Grivas,Matthew I. Milowsky,Matt D. Galsky,Rajesh Malik,Andrew P. Beelen	2022	3
6	Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). Journal of Clinical Oncology ·Shom Goel,Joyce O’Shaughnessy,Antoinette R. Tan,Boris Krastev,Hope S. Rugo,Philippe Aftimos,Denise A. Yardley,Andrić Zoran,Curt D. Wolfgang,Jessica A. Sorrentino,Wenli Tao,Andrew P. Beelen,Rajesh Malik,Sarika Jain	2021	2
7	278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients Annals of Oncology ·Boris Krastev,Ruhi Rai,Iurie Bulat,Marina Maglakelidze,C. Murias,H-T. Arkenau,Richard D. Baird,Andrew Wardley,Rebecca Roylance,Adrian Crijanovschi,Maia Gogiladze,Tao Wan,Andrew P. Beelen,Jessica A. Sorrentino	2020	4
8	334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection Annals of Oncology ·Iurie Bulat,Marina Maglakelidze,Boris Krastev,H-T. Arkenau,C. Murias,Richard D. Baird,Rebecca Roylance,Andrew Wardley,Adrian Crijanovschi,Maia Gogiladze,Yujie Lu,Amy McCullough,Suneil Jain,Curt D. Wolfgang,Rajesh Malik,Andrew P. Beelen	2020	4
9	Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers American Journal of Tropical Medicine and Hygiene ·Ronnatrai Rueangweerayut,Germana Bancone,Emma J. Harrell,Andrew P. Beelen,Supornchai Kongpatanakul,Jörg J. Möhrle,Vicki Rousell,Khadeeja Mohamed,Ammar Qureshi,Sushma Narayan,Nushara Yubon,Ann K. Miller,François Nosten,Lucio Luzzatto,Stephan Duparc,Jőrg‐Peter Kleim,Justin A. Green	2017	72
10	The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer Cancer Chemotherapy and Pharmacology ·Kevin M. Koch,E. Claire Dees,Shodeinde Coker,Nandi J. Reddy,Shelby D. Gainer,Nikita Arya,Andrew P. Beelen,Lionel D. Lewis	2017	4
11	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis Sexually Transmitted Diseases ·Jane R. Schwebke,Jeanne Marrazzo,Andrew P. Beelen,Jack D. Sobel	2015	19
12	A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours Journal of Chemotherapy ·Shodeinde Coker,Uday B. Dandamudi,Andrew P. Beelen,Nancy A. Crosby,Jan L. Fisher,Michael Obrocea,Marc S. Ernstoff,Lionel D. Lewis	2013	2
13	Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects British Journal of Clinical Pharmacology ·Ann K. Miller,Emma Harrell,Ye Li,Sharon Baptiste‐Brown,Jőrg‐Peter Kleim,Colin Ohrt,Stephan Duparc,Jörg J. Möhrle,Alison Webster,Sandra S. Stinnett,Arlene R. Hughes,Sandy Griffith,Andrew P. Beelen	2013	36
14	Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme Journal of Neuro-Oncology ·Kenneth F. Grossmann,Howard Colman,Wallace Akerley,Michael Glantz,Yuko Matsuoko,Andrew P. Beelen,Margaret K. Yu,John de Groot,Robert Aiken,Jeffery J. Olsen,Brent Evans,Randy L. Jensen	2012	29
15	Abstract A96: Phase 1 study of HSP90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer. Molecular Cancer Therapeutics ·Wolfram E. Samlowski,K. Papadopoulos,Anthony J. Olszanski,Kenton H. Zavitz,Daniel Cimbora,Siobhan Shawbell,Alfred H. Balch,Gary Mather,Andrew P. Beelen	2011	7
16	Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects British Journal of Clinical Pharmacology ·Deborah A. Smith,Kevin M. Koch,Nikita Arya,Carolyn J. Bowen,J. M. Herendeen,Andrew P. Beelen	2009	49
17	O1‐04‐07: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18‐month international multi‐center phase 3 trial Alzheimer s & Dementia ·Gordon Wilcock,Sandra E. Black,Alfred H. Balch,David A. Amato,Andrew P. Beelen,Lon S. Schneider,Robert C. Green,Edward A. Swabb,Kenton H. Zavitz	2009	11
18	Ethylene Glycol Toxicity Associated With Ischemia, Perforation, and Colonic Oxalate Crystal Deposition Journal of Clinical Gastroenterology ·Timothy B. Gardner,Harold L. Manning,Andrew P. Beelen,Robert Cimis,Justin Cates,Lionel D. Lewis	2004	9
19	An open-label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine Journal of Clinical Oncology ·J. M. Herendeen,Deborah A. Smith,Andrew G. Stead,Chester L. Bowen,Kevin M. Koch,Andrew P. Beelen	2004	4
20	The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer Cancer Chemotherapy and Pharmacology ·Lionel D. Lewis,Andrew P. Beelen,Bernard F. Cole,Paul K. Wallace,Jan L. Fisher,Mary Waugh,Peter A. Kaufman,Marc S. Ernstoff	2002	13

About Andrew P. Beelen

Andrew P. Beelen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 35 papers that have together received 553 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (14 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer therapeutics and mechanisms (3 papers), Estrogen and related hormone effects (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). The work is most often cited by research in Genetics (97 citations), Oncology (235 citations) and Pharmacology (49 citations). Andrew P. Beelen has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Lionel D. Lewis, Kevin M. Koch, Andrew G. Stead, L. D. Lewis, Nandi J. Reddy, Roger B. Cohen, Nancy Lewis, Nikita Arya, Deborah A. Smith and Carolyn J. Bowen. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact